Superconductivity in a two dimensional extended Hubbard model

The Roth's two-pole approximation has been used by the present authors to investigate the role of $d-p$ hybridization in the superconducting properties of an extended $d-p$ Hubbard model. Superconductivity with singlet $d_{x^2-y^2}$-wave pairing is treated by following Beenen and Edwards formalism. In this work, the Coulomb interaction, the temperature and the superconductivity have been considered in the calculation of some relevant correlation functions present in the Roth's band shift. The behavior of the order parameter associated with temperature, hybridization, Coulomb interaction and the Roth's band shift effects on superconductivity are studied.Comment: 14 pages, 8 figures, accepted for publication in European Physical Journal

Liposomes loaded with everolimus and coated with hyaluronic acid: A promising approach for lung fibrosis

Chronic lung allograft dysfunction (CLAD) and interstitial lung disease associated with collagen tissue diseases (CTD-ILD) are two end-stage lung disorders in which different chronic triggers induce activation of myo-/fibroblasts (LFs). Everolimus, an mTOR inhibitor, can be adopted as a potential strategy for CLAD and CTD-ILD, however it exerts important side effects. This study aims to exploit nanomedicine to reduce everolimus side effects encapsulating it inside liposomes targeted against LFs, expressing a high rate of CD44. PEGylated liposomes were modified with high molecular weight hyaluronic acid and loaded with everolimus (PEG-LIP(ev)-HA400kDa). Liposomes were tested by in vitro experiments using LFs derived from broncholveolar lavage (BAL) of patients affected by CLAD and CTD-ILD, and on alveolar macrophages (AM) and lymphocytes isolated, respectively, from BAL and peripheral blood. PEG-LIP-HA400kDa demonstrated to be specific for LFs, but not for CD44-negative cells, and after loading everolimus, PEG-LIP(ev)-HA400kDa were able to arrest cell cycle arrest and to decrease phospho-mTOR level. PEG-LIP(ev)-HA400kDa showed anti-inflammatory effect on immune cells. This study opens the possibility to use everolimus in lung fibrotic diseases, demonstrating that our lipids-based vehicles can vehicle everolimus inside cells exerting the same drug molecular effect, not only in LFs, but also in immune cells